Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

Documenti analoghi

• Risk factors for urinary tract infections among nursing home residents initiating sodium‐glucose cotransporter‐2 inhibitors
  di: Iju Shakya, et al.
  Pubblicazione: (2024)
• Association between sodium‐glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection
  di: Hsiao‐Wei Wang, et al.
  Pubblicazione: (2025)
• Sodium–glucose cotransporter 2 inhibitor increases risk of urinary tract infection: Evidence from mendelian randomization and meta‐analysis
  di: Jie Ren, et al.
  Pubblicazione: (2025)
• The efficacy and safety of sodium‐glucose cotransporter‐2 inhibitors in solid organ transplant recipients: A scoping review
  di: Hansa Mreyoud, et al.
  Pubblicazione: (2024)
• Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
  di: Yuri Sakai Ishizaki, et al.
  Pubblicazione: (2024)